Erasca, Inc.

NASDAQ:ERAS

Biotechnology

Healthcare
$13.76 -0.14%

-$0.02 today

Market cap
$4.83B
Beta
0.73
P/E (TTM)
-15.3
EPS (TTM)
-$0.91
52W Low $1.21High $24.28

Volume 8.94M

Average 6.79M

ERAS Total Non-current Liabilities

All obligations due after more than one year.

Erasca, Inc.NASDAQ: ERAS

Total Non-current Liabilities · Q3 FY2026 · quarter ended Sep 2026

Total non-current liabilities falls 12.8% from a year ago

Total non-current liabilities stood at $38.21M at the end of Q3 FY2026, down 12.8% from a year earlier and down 3.6% from the prior quarter. Over 3 fiscal years it compounded at -7.9% a year.

Context

  • Total non-current liabilities amounted to 3.8% of total assets at the end of Q3 FY2026, down 6.6 pp from a year earlier.
  • Total non-current liabilities increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether total non-current liabilities keeps falling in the next quarterly balance sheet after a -12.8% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$38.21M-3.6% QoQ
Last fiscal yearDec 2025
$42.47M-10.8% YoY
Year agoSep 2025
$43.8M-12.8% since
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-12.8%——
1 year-10.8%——
3-year CAGR-7.9%——
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
42.47M USD
Year-over-year change
-10.8%
4-year CAGR
+22.8%

Total Non-current Liabilities vs competitors

How ERAS compares with its peers on the latest reported figures

  • ERAS's Sep 2026 total non-current liabilities of $38.21M is the 5th highest of the 9 companies compared; the peer median is $53.72M.
  • Its year-over-year change of -12.8% is the 6th highest of 8, against a peer median of +10.1%.
  • Total non-current liabilities amounts to 3.8% of total assets for ERAS, versus a peer median of 17.1%.
ERAS Competitors Peer median
Total Non-current Liabilities for ERAS and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
RVMDRevolution Medicines, Inc.Jun 2026$1.36B +259.0%+88.4%31.5%
KURAKura Oncology, Inc.Mar 2026$443.17M +53.0%+234.3%67.9%
NUVBNuvation Bio Inc.Jun 2026$403.88M +94.2%+275.6%54.2%
VSTMVerastem, Inc.Mar 2026$79.19M -38.4%+65.1%34.8%
ERASErasca, Inc.Sep 2026$38.21M -12.8%-7.9%3.8%
IDYAIDEAYA Biosciences, Inc.Mar 2026$28.25M +10.1%+59.5%2.7%
TNGXTango Therapeutics, Inc.Sep 2026$28.12M -11.2%-38.3%2.7%
ORICORIC Pharmaceuticals, Inc.Mar 2026$3.43M -37.6%-21.0%0.8%
AVBPArriVent BioPharma, Inc. Common StockMar 2026$320K ——0.1%
Peer median (excluding ERAS) $53.72M+10.1%+65.1%17.1%

Competitors are the stored peer set for ERAS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents360.49M284.22M93.08M67.74M73.81M
Short-term Investments53.99M151.4M219.28M230.57M202.27M
Net Receivables0002.3M2.5M
Inventory00000
Other Current Assets100K748K1.1M8.18M7.66M
Total Current Assets420.02M444.5M320.68M308.79M286.24M
Property, Plant & Equipment (Net)33.31M65.23M60.19M48.54M42.33M
Goodwill00000
Intangible Assets00000
Long-term Investments44.77M2M10.05M142.16M66.13M
Tax Assets00000
Other Non-current Assets3.32M3.18M4.38M3.03M1.45M
Total Non-current Assets81.4M70.41M74.62M193.73M109.92M
Total Assets501.42M514.91M395.3M502.53M396.15M
Account Payables4.68M23.05M2M468K981K
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.16M2.33M10.78M10.65M12.07M
Total Current Liabilities26.22M48.69M26.16M31.4M28.51M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities158K573K566K362K399K
Total Non-current Liabilities18.66M54.37M52.46M47.63M42.47M
Total Liabilities44.89M103.06M78.61M79.03M70.98M
Common Stock12K15K15K28K28K
Retained Earnings(238.17M)(480.97M)(606.01M)(767.66M)(892.21M)
Accumulated OCI(162K)(1.04M)77K405K628K
Other Stockholders Equity0(0)000
Minority Interest00000
Total Equity456.53M411.85M316.69M423.5M325.17M
Total Debt18.79M55.1M55.86M51.89M47.14M
Net Debt(341.7M)(229.12M)(37.22M)(15.85M)(26.67M)

Erasca, Inc.

NASDAQ:ERAS

Intrinsic Alpha fair value

Locked

Current Price

$13.76

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.